Key risks
- PE multiple of 29.2 leaves limited valuation upside if near-term earnings growth falters — verify what underpins market confidence in forward earnings.
- Operating margins fluctuate from 20.06% to 29.31% across recent quarters — establish whether volatility reflects temporary factors or structural cost pressures.
- Consolidated revenue (typically ₹720–856 Cr) substantially exceeds standalone (₹320–361 Cr); verify profitability and operational control of consolidated entities.
- Pharma sector exposure to regulatory pricing pressure and generic competition — verify company's regulatory footprint and ability to offset margin pressure.
Generated analysis · source review pending